Chemomab Therapeutics to Participate in Upcoming Investor Conferences

News provided by

Feb 05, 2024, 07:00 ET

TEL AVIV, Israel, Feb. 5, 2024 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will participate in two upcoming investor conferences. Dr. Mor will deliver a corporate presentation and participate in one-on-one investor meetings at the Oppenheimer 34^th Annual Healthcare Life Sciences Conference, February 13-14, 2024 (virtual), and the Leerink Partners Global Biopharma Conference, March 11-13, 2024 in Miami, Florida. The Oppenheimer Conference presentation will be webcast live and will be available on the investor relations section of the Chemomab website for 90 days.

Oppenheimer 34^th Annual Healthcare Life Sciences Conference
Date:	February 14, 2024
Time:	8:00 am ET
Venue:	Virtual
Format:	Webcast presentation
Webcast Link:	https://wsw.com/webcast/oppenheimer33/cmmb/2744734
Information:	[email protected]
Leerink Partners Global BioPharma Conference
Date:	March 12, 2024
Time:	10:40am ET
Venue:	Fontainebleau Hotel
Format:	Live presentation
Information:	[email protected]

About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique and pivotal role of CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from three clinical trials of CM-101 in patients, including a Phase 2a liver fibrosis trial in NASH patients and an investigator-initiated study in patients with severe lung injury. A Phase 2 trial in primary sclerosing cholangitis has completed patient enrollment, with topline data expected midyear 2024. A CM-101 program for the treatment of systemic sclerosis is Phase 2-ready. For more information about Chemomab, visit chemomab.com.

Contacts:

Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
[email protected]
[email protected]

SOURCE Chemomab Therapeutics, Ltd.